Using AI to translate biomarkers from MRI and blood data into personalized insights, Ahead ultimately aims to become an \u201cintegration layer\u201d between cutting-edge diagnostics and the broader healthcare ecosystem, supporting its transition to preventive care. With prices starting at under $400 for a blood-test only package, and more than $4,000 for its most comprehensive offering, the company claims its approach has already uncovered previously unknown medical issues in around one in four early customers, ranging from cardiovascular and metabolic conditions to cancer and endometriosis.<\/p>\n
The funding round was led by RTP Global, with participation from Tiny.VC, Pareto 20 and a host of high-profile individuals, including the likes of MIT and DeepMind researcher Michiel Bakker and professional soccer player Cody Gakpo. Ahead aims to use the funding to scale its European expansion by signing up more partner clinics across Germany, the Netherlands and Austria, enhance its platform, and introduce new testing modalities.<\/p>\n
Longevity.Technology: In the US, the market for AI-enabled preventive health services is increasingly competitive, with companies like Function<\/a>, Superpower<\/a> and Hundred Health<\/a> entering the market in recent years amid growing consumer interest in data-driven health. In Europe, the scene is more fragmented, and Ahead is hoping to establish itself as a leader in the continent\u2019s shift from its established reactive healthcare model to one based on proactive prevention. To learn more about the company\u2019s approach, we sat down with CEO and co-founder Nick Lenten.<\/p>\n According to Lenten, the idea behind Ahead is that it will ultimately become a \u201csuper app for prevention.\u201d<\/p>\n \u201cI don\u2019t think we want, or need, \u00a0to do all the different action plan implementation steps ourselves, but we want to be the integration layer: the highest-quality data transformed into the right, medically backed insights,\u201d he says. \u201cI hope this becomes the prevention doctor in your pocket.\u201d<\/p>\n Building for the prevention revolution <\/p>\n While healthcare\u2019s move towards prevention is inevitable, Lenten says the tricky part for Ahead\u2019s founders was deciding the best way to build a startup that could play a role in that shift. \u00a0<\/p>\n \u201cDo you go B2B as a longevity technology company selling to healthcare providers, or do you go B2B2C via insurers?\u201d he says. \u201cOur belief was that to really innovate here, we needed to go direct-to-consumer first, and then work our way toward those models.\u201d<\/p>\n As a licensed medical provider, Ahead operates through partnerships with established clinics, and Lenten says the company aims to connect its users with their \u201clocal healthcare ecosystem\u201d for follow-ups with medical specialists.<\/p>\n \u201cFor example, if we find endometriosis, you might want to go to a specific endometriosis specialist,\u201d he explains. \u201cBut we also aim to support more lifestyle and subclinical next steps \u2013 like a personal trainer for the muscle imbalance we found in your back, and everything in between.\u201d<\/p>\n The company is aiming to bring the same level of health insight currently provided by high-end concierge clinics to a wider audience.<\/p>\n \u201cThis is how we developed our first package, which I call our Tesla Roadster,\u201d says Lenten. \u201cIt\u2019s cheaper than what you get elsewhere in the market, but still expensive in absolute terms: a $2,500 full-body MRI plus blood test check-up, working with high-quality partner clinics \u2013 first in Switzerland, and soon in other countries. We translate that with a combination of AI and our doctors into great insights, an action plan, and a beautiful report. That was our initial MVP experience.\u201d<\/p>\n Democratizing prevention <\/p>\n Since then, Lenten says Ahead has been \u201cchipping away\u201d at improving the product \u2013 making it more personalized, and also less expensive.<\/p>\n \u201cFor instance, now you can onboard with just a blood test,\u201d he adds. \u201cOver time, I want to create even cheaper entry points, so you can onboard with just your existing medical records.\u201d<\/p>\n While the company\u2019s packages leverage advanced diagnostics like full-body MRI, Lenten is keen to stress that he doesn\u2019t see the company as a diagnostics provider.<\/p>\n \u201cI see us as the translator of insights and data, the connector, and the center of gravity of your healthcare journey,\u201d he says. \u201cMRI and blood test protocols will eventually commoditize \u2013 the real magic happens after you have the data \u2013 doing something useful with it. That\u2019s where we aim to make our mark and build IP.\u201d<\/p>\n In terms of IP, Ahead\u2019s AI protocol is key, which Lenten says has been optimized to capture high-quality data on risk signals.<\/p>\n \u201cWe currently detect around 500 abnormalities from biomarkers extracted from images, blood results, and additional tests \u2013 like breast MRI, DEXA scans, lung CTs,\u201d he says. \u201cWe also track biomarkers over time, like brain age, and combine modalities (blood + MRI) to make better suggestions. We then process all of that into a detailed report, which a doctor reviews and signs off before it reaches the customer.\u201d<\/p>\n A \u2018city-by-city\u2019 strategy <\/p>\n Addressing the concerns raised by some about whether services like Ahead could potentially lead to \u201coverdiagnosis,\u201d Lenten shares a personal perspective. \u00a0<\/p>\n \u201cA smart doctor once told me: there\u2019s no such thing as overdiagnosis \u2013 there\u2019s over-treatment,\u201d he says. \u201cI still want the data; I just want to do smart things with it. Here\u2019s an example: we found a very small aneurysm in my brain. Clinically irrelevant today, but I\u2019m glad I have the data \u2013 if it changes in three years, that\u2019s meaningful. This is where a confident human doctor, backed by science and high-quality data, matters. Tracking over time matters.\u201d<\/p>\n Looking ahead, Lenten says that the funding will be used primarily to fund Ahead\u2019s product development and geographic expansion.<\/p>\n \u201cProduct-wise, our \u2018action plan\u2019 is the biggest focus \u2013 making it more personalized, goal-driven, and local,\u201d he explains. \u201cThen it\u2019s all about expansion. We\u2019re currently only in Zurich, but healthcare is local, so this is more a city-by-city play than country-by-country. We need to be awesome somewhere before being awesome everywhere. So, it\u2019ll be Geneva next, and then the next city \u2013 likely Germany, the Netherlands, or the UK.\u201d<\/p>\n \u201cOne day, I hope people think of us instead of \u2018Dr Google\u2019 because they can trust our data and the precision. We know your body better than a generic platform can, and we\u2019re willing to go into your local, regulated healthcare ecosystem to take the next step.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Ahead Health lands $6m in seed funding to accelerate digital-first approach to early detection of disease. Swiss preventive…\n","protected":false},"author":2,"featured_media":244701,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[123335,220,1302,103,397,396,61,1635,975,60,4591,43,123336,16017,86865,123337],"class_list":{"0":"post-244700","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-ahead-health","9":"tag-ai","10":"tag-exclusive","11":"tag-health","12":"tag-health-care","13":"tag-healthcare","14":"tag-ie","15":"tag-interview","16":"tag-investment","17":"tag-ireland","18":"tag-longevity","19":"tag-news","20":"tag-nick-lenten","21":"tag-prevention","22":"tag-preventive-health","23":"tag-whole-body-mri"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/244700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=244700"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/244700\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/244701"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=244700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=244700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=244700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Ahead Health is led by CEO Nick Lenten. <\/p>\n
<\/p>\n
<\/p>\n